Retatrutide vs Tirzepatide

Summary: Tirzepatide is FDA approved and delivered about 21 percent weight loss in SURMOUNT-1; retatrutide is an investigational triple agonist hitting roughly 24 percent at 48 weeks and 28 percent in TRIUMPH-4.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short version: tirzepatide is a dual GIP and GLP-1 receptor agonist that is FDA approved as Mounjaro for type 2 diabetes and Zepbound for obesity. Retatrutide is an investigational triple agonist that adds glucagon receptor activity to the same GIP and GLP-1 pair. In the head to head data we have so far, retatrutide produces larger weight loss than tirzepatide, but it is not yet approved by the FDA, and the Phase 3 TRIUMPH program is what will decide whether that approval actually lands.

If you are choosing a treatment right now, tirzepatide is the only one you can fill at a pharmacy. If you are reading about retatrutide because of the trial headlines, the practical answer is that it will most likely reach the US market in 2026 or 2027 if TRIUMPH-1 through TRIUMPH-4 hold up at FDA review.

The mechanism difference in one paragraph

Tirzepatide binds two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Activating both at once produces stronger glycemic control and stronger appetite suppression than activating GLP-1 alone, which is why tirzepatide outperformed semaglutide in the SURMOUNT-2 head to head ^[2]. Retatrutide adds a third agonist arm: the glucagon receptor. Glucagon agonism sounds counterintuitive for weight loss because glucagon raises blood sugar, but at the pharmacologic doses used in retatrutide it increases resting energy expenditure and lipolysis without compromising the glycemic benefit of GIP and GLP-1 co-agonism ^[1]. The net result is more weight lost per week of treatment.

Both molecules come from the same company. Lilly built retatrutide on the same modified peptide scaffold approach that produced tirzepatide, which is why the dosing schedule (once weekly subcutaneous injection) and the side effect profile (GI dominant, dose dependent) look so similar between the two.

What the weight loss data actually shows

This is the comparison most people came here for. The trials were not run head to head, so you have to compare across studies, but the doses, durations, and populations are similar enough to make the comparison meaningful.

SURMOUNT-1 is the Phase 3 obesity trial that supported Zepbound's FDA approval. Mean weight loss at the 15 mg maximum dose was 20.9 percent at 72 weeks, with about 57 percent of participants losing at least 20 percent of their body weight ^[2]. That number is the current ceiling for any FDA approved weight loss drug.

The retatrutide Phase 2 trial published by Jastreboff and colleagues in the New England Journal of Medicine in 2023 was the result that put the molecule on every endocrinologist's radar. At 48 weeks, the 12 mg dose produced 24.2 percent mean weight loss, and the curve had not plateaued ^[1]. That last detail is the important one. Tirzepatide at 72 weeks had largely flattened. Retatrutide at 48 weeks was still going down.

TRIUMPH-4 is the Phase 3 readout Lilly released in 2025. The topline number, roughly 28 percent mean weight loss at 76 weeks, is the highest ever reported for a weight loss drug in a Phase 3 setting ^[3]. Final journal publication and FDA submission are the next steps. Assuming the data holds, retatrutide will likely become the highest efficacy weight loss drug on the US market when it launches.

Where retatrutide pulls ahead and where tirzepatide still wins

The efficacy data favors retatrutide. Everything else, for now, favors tirzepatide.

Tirzepatide is available. You can call a doctor today, get a prescription, and inject your first dose this week. Insurance coverage for Zepbound has expanded since 2024, and Lilly's direct-to-consumer vial program through LillyDirect put the brand drug in reach for cash-pay patients at lower price points than the auto-injector pens. Retatrutide is not available at any pharmacy. The only legal way to take it in the US is to enroll in a clinical trial, and the TRIUMPH program is closed to most new enrollment.

Tirzepatide has four years of real-world prescribing data. We know what happens at year three of continuous therapy because actual humans have been on it that long. Retatrutide's longest published exposure is 48 weeks of Phase 2 plus the 76 week TRIUMPH topline. Long-term safety, particularly around the glucagon receptor arm, is still being studied.

Retatrutide produces more weight loss per week of treatment and appears to keep working past the point where tirzepatide flattens. If your treatment goal is to lose more than 25 percent of body weight, the published tirzepatide curve does not get you there reliably. Retatrutide might. That is the practical case for waiting if you can afford to wait.

Side effects and tolerability

The side effect profile is the same general shape for both drugs: GI dominant, dose dependent, and worst during titration. Nausea, diarrhea, constipation, and vomiting top the list for both. Most reports resolve over the first few weeks at a given dose. The retatrutide Phase 2 trial reported GI side effects in 67 to 90 percent of the high-dose arm depending on category, with discontinuation rates in the same range as tirzepatide in SURMOUNT-1 (about 6 to 7 percent for drug-related adverse events) ^[1].

The new safety questions specific to retatrutide come from the glucagon receptor arm. Phase 2 data showed small increases in heart rate (about 3 to 7 beats per minute at the higher doses) and transient elevations in some liver enzymes that resolved on continued therapy ^[1]. The diabetes trial of retatrutide published in The Lancet also found that glycemic control was preserved or improved despite glucagon agonism, which was the main physiologic question going into the program ^[5]. Phase 3 TRIUMPH data so far has not surfaced a new safety signal that would block approval.

Tirzepatide's label carries a boxed warning for thyroid C-cell tumors based on rodent data. There is no human signal but the warning is on every GLP-1 and GIP/GLP-1 drug in this class ^[4]. Retatrutide's eventual label will almost certainly carry the same warning.

Dosing

Both drugs are once weekly subcutaneous injections. Both use a multi-week titration schedule to manage GI side effects.

Tirzepatide's FDA-approved obesity titration is 2.5 mg for 4 weeks, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, stepping up every 4 weeks if tolerated ^[4]. Most patients land on 10 mg or 15 mg as their maintenance dose.

Retatrutide's Phase 2 and Phase 3 trials used a similar schedule, starting at 2 mg or 4 mg and stepping up by 2 to 4 mg every 4 weeks to a maximum of 12 mg ^[1]. Final labeled dosing will be set by the FDA based on TRIUMPH data and will probably look similar to what was studied.

Retatrutide vs tirzepatide vs semaglutide

Adding semaglutide rounds out the comparison most people are actually running in their heads.

Semaglutide was the breakthrough. Tirzepatide raised the ceiling. Retatrutide raises it again. Each step up in receptor coverage has produced a step up in mean weight loss in clinical trials, and the pattern lines up with the underlying pharmacology in a way that gives reasonable confidence the TRIUMPH numbers will hold.

If you want a drug today, semaglutide and tirzepatide are the two real options, and tirzepatide is the higher-efficacy choice. If you want the most weight loss the science will offer in the near future and you can wait, retatrutide is what you are waiting for.

Cost and access

Tirzepatide is on the US market and is the cheaper of the two options because retatrutide has no commercial price yet.

Zepbound retail is about $1,060 per month for the auto-injector pens at most US pharmacies, and Lilly's direct vial program prices the lower doses at $349 to $499 per month for cash-pay patients without insurance. Mounjaro for type 2 diabetes is covered by most commercial plans and many Medicare Part D plans. Compounded tirzepatide existed at lower price points during the 2024 shortage, but the FDA removed tirzepatide from the shortage list in late 2024, and 503A compounding for branded shortage drugs is no longer broadly legal. Pharmacy availability of compounded tirzepatide has narrowed sharply since.

Retatrutide is not sold anywhere legally in the US. Peptide vendors selling vials labeled "retatrutide" online are selling research-grade material that has not been validated for human dosing and is not legal to dispense for medical use. The risk profile of buying from those channels is the same as for any unapproved injectable, and the dosing accuracy and sterility have no oversight. Wait for the FDA approval.

When retatrutide might reach the market

Lilly has not given a binding date. Based on TRIUMPH-4 topline readout in 2025, the typical FDA review timeline, and Lilly's stated intent to file for obesity, a plausible US launch window is late 2026 to 2027. Diabetes and MASH indications are likely to follow. None of this is guaranteed. A late safety signal in TRIUMPH-1, TRIUMPH-2, or TRIUMPH-3, or a manufacturing constraint, could push the date.

What to do with this comparison right now

If you have a treatment goal of 10 to 20 percent body weight loss, tirzepatide already does that. Starting it now and reaching your goal in 2026 is a faster path than waiting for retatrutide approval.

If your goal is over 25 percent body weight loss, tirzepatide may not reach that ceiling for you. The published curve plateaus near 21 percent on average, with individual variation up and down. You have two options: start tirzepatide now, run it to its individual plateau, and then switch to retatrutide if and when it is approved. Or wait for retatrutide if you can. There is no medical reason you cannot switch, since both drugs come from the same family and share most of the same receptor activity.

If you have type 2 diabetes, tirzepatide as Mounjaro is the FDA approved choice and is well established. Retatrutide's diabetes program is in progress but is not yet at the regulatory stage.

Is retatrutide better than tirzepatide?

Retatrutide produces more weight loss in clinical trials, roughly 24 to 28 percent versus 21 percent for tirzepatide at maximum doses. Tirzepatide is FDA approved and available. Retatrutide is investigational.

When will retatrutide be FDA approved?

Lilly has not committed to a date. Based on the 2025 TRIUMPH-4 topline readout and typical FDA timelines, a US launch in late 2026 or 2027 is plausible if the remaining TRIUMPH trials hold up.

Is retatrutide a triple agonist?

Yes. Retatrutide activates three receptors: GIP, GLP-1, and glucagon. Tirzepatide activates two: GIP and GLP-1. The glucagon arm is what makes retatrutide the first triple agonist in late-stage development.

How does retatrutide compare to tirzepatide vs semaglutide?

Semaglutide (Wegovy) hits one receptor and produces about 15 percent weight loss in STEP 1. Tirzepatide hits two and produces about 21 percent in SURMOUNT-1. Retatrutide hits three and is producing about 24 to 28 percent in Phase 2 and Phase 3 data.

Can I buy retatrutide now?

Not legally for medical use in the US. Retatrutide is not FDA approved, and pharmacies cannot dispense it. Peptide vendors selling research-grade vials online operate outside the medical supply chain and are not a safe source for injectable use.

Is retatrutide made by the same company as tirzepatide?

Yes. Both are Eli Lilly molecules. Retatrutide was developed using the same modified peptide chemistry approach Lilly used for tirzepatide, which is why the dosing schedules and side effect profiles look so similar.

What are the side effects of retatrutide compared to tirzepatide?

The GI side effect profile (nausea, vomiting, diarrhea, constipation) is similar in incidence and severity. Retatrutide also shows small increases in resting heart rate from the glucagon receptor arm. Long-term comparative safety data does not yet exist.

Will retatrutide replace tirzepatide?

For patients who want maximum weight loss, retatrutide is positioned to become the higher-efficacy option once it is approved. Tirzepatide will remain available and is likely to keep a large market share for patients with lower weight loss targets or established response on the drug.

Does retatrutide work for type 2 diabetes?

Yes. The Phase 2 trial in The Lancet showed strong glycemic control with retatrutide despite the glucagon receptor activity. A dedicated diabetes Phase 3 program is in progress.

Bottom line

Tirzepatide is the strongest weight loss drug you can fill at a pharmacy today. Retatrutide is the strongest weight loss drug in late-stage development and will likely move that ceiling up by another 5 to 7 percentage points of mean weight loss if TRIUMPH-1 through TRIUMPH-4 confirm the early data. Both are Lilly molecules, both are once weekly injections, both share the same family of side effects. The choice between them, for most patients, is really a choice between starting now or waiting 12 to 24 months for the next step up in efficacy.